Related Party Transactions |
3 Months Ended |
|---|---|
Mar. 31, 2026 | |
| Related Party Transactions [Abstract] | |
| Related Party Transactions | 13. RELATED PARTY TRANSACTIONS Relationship with Factor Bioscience Inc. Matt Angel, Ph.D., the Company’s Chief Executive Officer and a member of its Board of Directors, is also the majority owner, Chief Executive Officer and chairman of Factor. During the quarter ended March 31, 2026, the Company completed the Asset Acquisition involving Factor. Additional information regarding the Asset Acquisition is included in Note 12. As of March 31, 2026, there were no amounts due to or from Factor included in the accompanying consolidated balance sheets. In November 2025, Erigen entered into the Factor MSA, which was assigned to the Company in connection with the Closing pursuant to the Asset Purchase Agreement. For additional information regarding the Factor MSA, please see Note 1 under “—Acquisition of Erigen Assets.” The Company also entered into a private placement financing during the quarter in which Factor invested $0.5 million. Additional information regarding this financing is included in Note 1 under “—Private Placement.” Advisory Agreement with Andrew Fang In March 2026, the Board of the Company approved and authorized the execution of an advisory agreement dated April 1, 2026 (the “Advisory Agreement”), with Andrew Fang, who is an immediate family member of the owner of Lotus, a major shareholder of the Company, to provide advisory services to the Company. Pursuant to the Advisory Agreement, Andrew Fang will be paid an hourly rate for services provided. Services under the arrangement began April 2026. As of March 31, 2026, no amounts were incurred or payable under this arrangement. |